CompletedEarly Phase 1ketamine

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

Sponsored by AstraZeneca

NCT ID
NCT00985933
Target Enrollment
20 participants
Start Date
2010-02
Est. Completion
2011-04

About This Study

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Conditions Studied

HealthyMemory Impairment

Interventions

  • AZD8529
  • Placebo to match AZD8529

Eligibility

Age:21 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

* Right handed
* 12th grade education or equivalent
* Able to read and write English as primary language

Exclusion Criteria:

* History of head injury
* Substance abuse or dependence
* History of claustrophobia

Study Locations (1)

Research Site
New Haven, Connecticut, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source